« Back to Medicines list

Comtess

  • Name:

    Comtess

  • Company:
    info
  • Active Ingredients:

    Entacapone

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 13/10/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 10/5/2018
print

Print ViewKeyword Search SPC

Orion Pharma (Ireland) Ltd

Orion Pharma (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Bufomix Easyhaler 160 micrograms/4.5 micrograms Active Ingredients Budesonide, Formoterol fumarate dihydrate
Medicine Name Bufomix Easyhaler 320 micrograms/9 micrograms Active Ingredients Budesonide, Formoterol fumarate dihydrate
Medicine Name Bufomix Easyhaler 80 micrograms/4.5 micrograms Active Ingredients Budesonide, Formoterol fumarate dihydrate
Medicine Name Comtess Active Ingredients Entacapone
Medicine Name Dexdor 100 micrograms/ml concentrate for solution for infusion Active Ingredients Dexmedetomidine hydrochloride
Medicine Name Divigel 0.1% Gel Active Ingredients Estradiol Hemihydrate
Medicine Name Eldepryl 5 mg Tablets Active Ingredients Selegiline Hydrochloride
Medicine Name Fareston Active Ingredients Toremifene Citrate
Medicine Name Indivina Active Ingredients Estradiol valerate, Medroxyprogesterone Acetate
Medicine Name Indivina 1 mg/2.5 mg tablets Active Ingredients Estradiol valerate, Medroxyprogesterone Acetate
Medicine Name Indivina 1 mg/5 mg tablets Active Ingredients Estradiol valerate, Medroxyprogesterone Acetate
Medicine Name Indivina 2 mg/5 mg tablets Active Ingredients Estradiol valerate, Medroxyprogesterone Acetate
Medicine Name Methotrexate Orion 10 mg tablets Active Ingredients Methotrexate disodium
Medicine Name Methotrexate Orion 2.5 mg tablets Active Ingredients Methotrexate disodium
Medicine Name Stalevo 100 mg/25 mg/200 mg film-coated tablets Active Ingredients Carbidopa, Entacapone, Levodopa
Medicine Name Stalevo 125 mg/31.25 mg/200 mg film-coated tablets Active Ingredients Carbidopa, Entacapone, Levodopa
Medicine Name Stalevo 150 mg/37.5 mg/200 mg film-coated tablets Active Ingredients Carbidopa, Entacapone, Levodopa
Medicine Name Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Active Ingredients Carbidopa, Entacapone, Levodopa
Medicine Name Stalevo 200 mg/50 mg/200 mg film-coated tablets Active Ingredients Carbidopa, Entacapone, Levodopa
Medicine Name Stalevo 50 mg/12.5 mg/200 mg film-coated tablets Active Ingredients Carbidopa, Entacapone, Levodopa
Medicine Name Stalevo 75 mg/18.75 mg/200 mg film-coated tablets Active Ingredients Carbidopa, Entacapone, Levodopa
Medicine Name Toilax micro enema suspension Active Ingredients Bisacodyl
Medicine Name Veramil 120 mg Film-coated Tablets Active Ingredients verapamil hydrochloride
Medicine Name Veramil 80 mg Film-coated Tablets Active Ingredients verapamil hydrochloride
1 - 0 of 24 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13 October 2020 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Free text change information supplied by the pharmaceutical company

The manufacturer information has been updated on the leaflet.

Updated on 12 August 2019 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 10 May 2018 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 January 2017 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 January 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 11 January 2017 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The text has been updated to include the warning of soya lecithin, as the coating of the tablets contains soya lecithin in the product information.

Updated on 11 January 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 3 February 2016 SPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Date of revision of text updated (due to update in PIL contact details), no further changes.

Updated on 3 February 2016 PIL

Reasons for updating

  • Change to date of revision

Updated on 5 February 2015 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The SmPC template has been updated to include a statement about the local 'Reporting of suspected adverse reactions'

Updated on 4 February 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 21 December 2013 SPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

No changes to SmPC text, the Package Leaflet has been updated.

Updated on 17 December 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change of distributor details

Updated on 7 February 2013 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The following text has been added (to replace the previous text that referred to pathological gambling, increased libido etc):

Section 4.4:
Patients should be regularly monitored for the development of impulse control disorders. Patients
and carers should be made aware that behavioural symptoms of impulse control disorders including
pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge
eating and compulsive eating can occur in patients treated with dopamine agonists and/or other
dopaminergic treatments such as Comtess in association with levodopa. Review of treatment is
recommended if such symptoms develop.

Section 4.8:
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive
spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine
agonists and/or other dopaminergic treatments such as Comtess in association with levodopa

Updated on 4 February 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 21 June 2010 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.2 (Posology and method of administration) title Children has changed to Pediatric population
In section 4.4 (Special warnings and precautions for use) insertion of one sentence ' Entacapone therapy should be administered cautiously to patients with ischemic heart disease.'
and
For patients..........weight decrease. Prolonged or peristent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered.
In section 4.6 (Pregnancy and lactation) has changed to Fertility, pregnancy and lactation
In section 4.8 (Undesirable effects) addition of Cardiac disorders** section and below an additional paragraph to cover ** The incidence.........receiving entacapone.
In section 5.3 (Preclinical safety data) the first word has changed from Preclinical data to Non-clinical data.
In section 10  (Date of Revision of the Text) is 10 June 2010

Updated on 1 October 2009 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 23 May 2007 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 21 May 2007 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 (Special earnings and precautions for use) - 'For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.' has been added.
 
Section 4.8 (Undesirable effects) - The following have been added to this section; Colitis.  Skin, hair, beard and nail discolourations.  Hepatitis with mainly cholestatic features.

Updated on 27 April 2005 PIL

Reasons for updating

  • Change to date of revision

Updated on 15 April 2005 SPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 8 December 2003 SPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 4 June 2003 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)